REG - Oncimmune Hldgs PLC - Block Listing Six Monthly Return

Oncimmune HoldingsAnnouncement

16/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220316:nRSP8593Ea&default-theme=true

RNS Number : 8593E  Oncimmune Holdings PLC  16 March 2022

16 March 2022

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Block Listing Six Monthly Return

 

 

Oncimmune makes the following notification pursuant to Schedule Six of the AIM
Rules for Companies regarding its existing block admission arrangements in
respect of Oncimmune Holdings plc 2016 Unapproved and EMI Share Option Plans
(the "Share Option Plans").

 

 Name of applicant:                                                          Oncimmune Holdings plc

 Name of scheme:                                                             Oncimmune Holdings plc 2016 Unapproved and EMI Share Option Plans

 Period of return:                                                           16 September 2021 to 15 March 2022

 Balance of unallotted securities under scheme(s) from previous return:      5,805,745

 Plus: The amount by which the block scheme(s) has been increased since the  0
 date of the last return (if any increase has been applied for):

 Less: Number of securities issued/allotted under scheme(s) during period:   18,399

 Equals: Balance under scheme(s) not yet issued/allotted at end of period:   5,787,346

 

 

For further information:

 

Oncimmune Holdings plc

Ron Kirschner, Company Secretary

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRUVAORUSUOAAR